Servier in Chinese deal for lucitanib

Servier (Neuilly-sur-Seine, France) partnered with the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (Shanghai, China) to develop cancer compound lucitanib ( E-3810) in China. The partners will collaborate to provide evidence of clinical benefit of lucitanib in "Chinese indications" through national clinical trials. SIMM will also conduct biomarker research. The partners could not be reached for details. ...